| 新型P2Y12受体抑制剂替格瑞洛临床研究进展 |
| |
| 引用本文： | 章霞,柯永胜.新型P2Y12受体抑制剂替格瑞洛临床研究进展[J].中国临床药理学与治疗学,2014(4):459-464. |
| |
| 作者姓名： | 章霞 柯永胜 |
| |
| 作者单位： | 皖南医学院弋矶山医院心内科,安徽芜湖241000 |
| |
| 摘 要： | 抗血小板药物是急性冠脉综合征（Acute Coronary Syndrome,ACS）治疗的基石，对防治心肌缺血和介入并发症是有益的。目前治疗ACS和经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）指南推荐使用的口服抗血小板药物包括氯吡格雷、替格瑞洛、普拉格雷联合阿司匹林双重抗血小板治疗预防复发性缺血事件。本文对新型P2Y12受体抑制剂替格瑞洛的药代动力学和药效学特点以及在ACS患者中的循证医学证据作一介绍。
|
| 关 键 词： | 急性冠脉综合征 替格瑞洛 氯吡格雷 抗血小板药物 经皮冠状动脉介入治疗 |
Clinical research of new type P2Y12 Receptor inhibitor ticagrelor |
| |
| ZHANG Xia,KE Yong-sheng.Clinical research of new type P2Y12 Receptor inhibitor ticagrelor[J].Chinese Journal of Clinical Pharmacology and Therapeutics,2014(4):459-464. |
| |
| Authors: | ZHANG Xia KE Yong-sheng |
| |
| Institution: | (Department of Cardiology, Yij ishan Hospital, Wannan Medical College, Wuhu 241000, Anhui , China) |
| |
| Abstract: | Antiplatelet therapy is widely used with proven beneft for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor,a new P2Y12 receptor inhibitor ,as well as evidence-basedmedical evidence in patients with coronary artery disease. |
| |
| Keywords: | acute coronary syndrome ticagrelor clopidogrel antiplatelet percutaneouscoronary intervention |
| 本文献已被 维普 等数据库收录！ |
|
